A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine [FOLLOW-UP OF 700217216]

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with Memantine [FOLLOW-UP OF 700217216]

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2014

At a glance

  • Drugs Memantine (Primary)
  • Indications Asperger syndrome; Autistic disorder; Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jul 2013 Planned number of patients changed from 96 to 450 as reported by European Clinical Trials Database.
    • 01 Jul 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top